Panelists discuss how they perform comprehensive molecular testing using immunohistochemistry, FISH, and next-generation sequencing to identify IDH mutations and other critical markers like CDKN2A/2B loss that guide treatment decisions and tumor classification.
Content above is prompted by the following:
Molecular testing workflow begins with immunohistochemistry for IDH1 R132H mutation, which identifies 85% to 90% of IDH-mutant gliomas and provides rapid initial results. This is followed by fluorescence in situ hybridization (FISH) testing for 1p19q codeletion to distinguish between oligodendrogliomas (IDH-mutant with 1p19q codeletion) and astrocytomas (IDH-mutant without codeletion). However, 10% to 15% of patients require next-generation sequencing to identify non-canonical IDH mutations, which can delay diagnosis by several weeks but is crucial for accurate classification.
Additional molecular markers significantly impact treatment planning, particularly CDKN2A/2B homozygous deletion, which automatically upgrades IDH-mutant astrocytomas to grade 4 regardless of histologic appearance. Other alterations like CDK4/6 amplification and growth factor pathway mutations, while not definitively changing diagnosis, warrant closer monitoring and may influence treatment intensity. The ATRX retention status can provide additional diagnostic clues, with retained ATRX more likely indicating IDH wild-type tumors.
Next-generation sequencing becomes mandatory when standard immunohistochemistry returns negative in clinically suspected IDH-mutant cases, as this identifies non-canonical IDH1 mutations and rare IDH2 mutations. Brain stem gliomas represent a particularly important group where molecular testing may reveal IDH alterations that dramatically change prognosis and treatment options. The comprehensive molecular profiling ensures accurate diagnosis and prevents missed opportunities for targeted therapy, particularly as IDH inhibitors become available for these molecularly defined patient populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.